Scientists at Fred Hutch Cancer Center have made a groundbreaking discovery in the fight against Epstein-Barr Virus (EBV), a pathogen affecting up to 95% of the global population and linked to various cancers and chronic diseases. The team, led by Dr. Andrew McGuire, has developed human monoclonal antibodies that effectively block EBV from infecting human immune cells, offering hope for patients at high risk of EBV-related complications.
The study, published in Cell Reports Medicine, utilized mice with human antibody genes to create new genetically human monoclonal antibodies. These antibodies target two key antigens on the virus's surface, preventing EBV from binding to and entering human immune cells. The research identified two monoclonal antibodies against gp350 and eight against gp42, with one successfully blocking EBV infection in mice with human immune systems.
The challenge of finding human antibodies that block EBV from infecting B cells, a common issue with other viruses, was addressed by the team's innovative approach. This discovery not only highlights the importance of these antibodies but also paves the way for developing protective antibodies against other pathogens.
The potential impact of this research is significant, especially for transplant recipients who are at high risk of EBV-related complications. Post-transplant lymphoproliferative disorders (PTLD), often caused by EBV, are a leading cause of morbidity and mortality after organ transplantation. The antibodies could prevent EBV infection and activation in these high-risk patients, reducing the incidence of PTLD and the need for reduced immunosuppression.
Fred Hutch has filed for intellectual property rights, and the team is working with collaborators to advance a potential therapy for immunocompromised patients. The next steps include testing the therapy's safety in healthy adults and, if successful, moving forward with clinical trials in the relevant patient population. This discovery marks a significant stride in the scientific community's efforts to protect against EBV, offering hope for improved patient outcomes and quality of life.
